Valion Bio, Inc.: interim CEO's 30-day assessment

What happened Valion Bio, Inc. announced that on Oct 21, 2026 it issued a press release regarding the company's new interim chief executive officer, Dean Zikria's first 30 days' assessment. A copy of the press release is filed as Exhibit 99.1 to the Current Report on Form 8-K and is incorporated by reference.

Key details

• The press release was issued on Oct 21, 2026 and relates to Dean Zikria, the company's interim chief executive officer.
• The disclosure was reported under Item 8.01 (Other events) of Form 8-K.
• A copy of the press release is included as Exhibit 99.1 to the filing.

Why it may matter The filing reports an Item 8.01 other event: a corporate press release about the interim CEO's first 30 days' assessment. The Current Report includes Exhibit 99.1 containing the press release. The filing does not show why the insider traded or why the company acted.